Recent progress in lentiviral vector mass production

Biochemical Engineering Journal

Volumn 48, Issue 3, 2010, Pages 362-377

  Ansorge, Sven ^a,b   Henry, Olivier ^b   Kamen, Amine ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

Animal and insect cell culture engineering; Large scale production; Lentiviral vectors; Scalable processes; Viral vectors; Virus production

Indexed keywords

INSECT CELL CULTURE; LARGE-SCALE PRODUCTION; LENTIVIRAL VECTOR; VIRAL VECTORS;

ANIMALS; CELL CULTURE; GENE THERAPY; GENE TRANSFER; MACHINE TOOLS; PRODUCTION ENGINEERING; VECTORS; VIRUSES;

ANIMAL CELL CULTURE;

BUTYRIC ACID; CHLOROQUINE; CHOLESTEROL; LENTIVIRUS VECTOR; LIPID; VIRUS PROTEIN;

ASSAY; CELL CULTURE; CELL LINE; DOWNSTREAM PROCESSING; GENETIC TRANSDUCTION; HUMAN; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; RELIABILITY; RETROVIRUS; REVIEW; SUPERNATANT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS GENE; VIRUS PARTICLE; VIRUS TRANSCRIPTION;

ANIMALIA; HEXAPODA;

EID: 75349106422     PISSN: 1369703X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bej.2009.10.017     Document Type: Review

References (191)

1. Azzouz M., Kingsman S.M., and Mazarakis N.D. Lentiviral vectors for treating and modeling human CNS disorders. J. Gene. Med. 6 (2004) 951-962
2. Cockrell A.S., and Kafri T. Gene delivery by lentivirus vectors. Mol. Biotechnol. 36 (2007) 184-204
3. Quinonez R., and Sutton R.E. Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 21 (2002) 937-951
4. Salmon P., and Trono D. Lentiviral vectors for the gene therapy of lympho-hematological disorders. Curr. Top. Microbiol. Immunol. 261 (2002) 211-227
5. Wright J.F. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther. 20 (2009) 1-9
6. Stewart H.J., Leroux-Carlucci M.A., Sion C.J., Mitrophanous K.A., and Radcliffe P.A. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther. 16 (2009) 805-814
7. Wang G.P., Ciuffi A., Leipzig J., Berry C.C., and Bushman F.D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17 (2007) 1186-1194
8. Schröder A.R.W., Shinn P., Chen H., Berry C., Ecker J.R., and Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 (2002) 521-529
9. Amado R.G., and Chen I.S. Lentiviral vectors-the promise of gene therapy within reach?. Science 285 (1999) 674-676
10. Vigna E., and Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2 (2000) 308-316
11. Segura M.M., Kamen A., and Garnier A. Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv. 24 (2006) 321-337
12. Li S., Kimura E., Fall B.M., Reyes M., Angello J.C., Welikson R., Hauschka S.D., and Chamberlain J.S. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther. 12 (2005) 1099-1108
13. Higashikawa F., and Chang L.-J. Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280 (2001) 124-131
14. Vogt V.M., and Simon M.N. Mass determination of Rous Sarcoma Virus virions by scanning transmission electron microscopy. J. Virol. 73 (1999) 7050-7055
15. Desmaris N., Bosch A., Salaun C., Petit C., Prevost M.C., Tordo N., Perrin P., Schwartz O., de Rocquigny H., and Heard J.M. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol. Ther. 4 (2001) 149-156
16. Lever A.M., Strappe P.M., and Zhao J. Lentiviral vectors. J. Biomed. Sci. 11 (2004) 439-449
17. Ramezani A., and Hawley R.G. Overview of the HIV-1 lentiviral vector system. Curr. Protoc. Mol. Biol. Suppl. 60 (2002) 16. 21. 1-16. 21.15
18. Throm R.E., Ouma A.A., Zhou S., Chandrasekaran A., Lockey T., Greene M., De Ravin S.S., Moayeri M., Malech H.L., Sorrentino B.P., and Gray J.T. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113 (2009) 5104-5110
19. Kohn D.B. Lentiviral vectors ready for prime-time. Nat. Biotech. 25 (2007) 65-66
20. Follenzi A., Santambrogio L., and Annoni A. In: Herzog H.W. (Ed). Immune Responses to Lentiviral Vectors, in Current Gene Therapy (2007), Bentham Science Publishers 306-315
21. Watson D.J., Kobinger G.P., Passini M.A., Wilson J.M., and Wolfe J.H. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 5 (2002) 528-537
22. Jakobsson J., and Lundberg C. Lentiviral vectors for use in the central nervous system. Mol. Ther. 13 (2006) 484-493
23. Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., Emborg M., Hantraye P., Déglon N., and Aebischer P. Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160 (1999) 1-16
24. Breckpot K., Aerts J.L., and Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 14 (2007) 847-862
25. Wang B., He J., Liu C., and Chang L.-J. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 24 (2006) 3477-3489
26. Dullaers M., Meirvenne S.V., Heirman C., Straetman L., Bonehill A., Aerts J.L., Thielemans K., and Breckpot K. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 13 (2005) 630-640
27. Breckpot K., Dullaers M., Bonehill A., Meirvenne S.V., Heirman C., Greef C.D., Bruggen P.v.d., and Thielemans K. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J. Gene Med. 5 (2003) 654-667
28. ®) for a phase I/II clinical trial. 20th ESACT Meeting. Dresden, Germany (2007)
29. MacGregor R.R. A phase I open label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum. Gene Ther. 12 (2001) 2028-2029
30. Slepushkin V., Chang N., and Cohen R. Large-scale purification of a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange capsule. Bioprocess J. 2 (2003) 89-95
31. Schonely K., Afable C., Slepushkin V., Lu X., Andre K., Boehmer J., Bengston K., Doub M., Cohen R., Berlinger D., Slepushkina T., Chen Z., Li Y., Binder G., Davis B., Humeau L., and Dropulic B. QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioprocess J. 2 (2003) 39-47
32. Levine B.L., Humeau L.M., Boyer J., MacGregor R.-R., Rebello T., Lu X., Binder G.K., Slepushkin V., Lemiale F., Mascola J.R., Bushman F.D., Dropulic B., and June C.H. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 17372-17377
33. Chang A.H., and Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol. Ther. 15 (2007) 445-456
34. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
35. Naldini L., Blomer U., Gage F.H., Trono D., and Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11382-11388
36. Zufferey R., and Trono D. Production of high-titer lentiviral vectors. Curr. Protoc. Hum. Genet. (2000) 12.10.1-12.10.12
37. Ni Y., Sun S., Oparaocha I., Humeau L., Davis B., Cohen R., Binder G., Chang Y.N., Slepushkin V., and Dropulic B. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 7 (2005) 818-834
38. Ikeda Y., Takeuchi Y., Martin F., Cosset F.-L., Mitrophanous K., and Collins M. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21 (2003) 569-572
39. Wu X., Wakefield J.K., Liu H., Xiao H., Kralovics R., Prchal J.T., and Kappes J.C. Development of a novel trans-lentiviral vector that affords predictable safety. Mol. Ther. 2 (2000) 47-55
40. Sastry L., Xu Y., Johnson T., Desai K., Rissing D., Marsh J., and Cornetta K. Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication-competent viruses. Mol. Ther. 8 (2003) 830-839
41. Miskin J., Chipchase D., Rohll J., Beard G., Wardell T., Angell D., Roehl H., Jolly D., Kingsman S., and Mitrophanous K. A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors. Gene Ther. 13 (2005) 196-205
42. Escarpe P., Zayek N., Chin P., Borellini F., Zufferey R., Veres G., and Kiermer V. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol. Ther. 8 (2003) 332-341
43. Sinn P.L., Sauter S.L., and McCray P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 12 (2005) 1089-1098
44. Hanawa H., Yamamoto M., Zhao H., Shimada T., and Persons D.A. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken [beta]-globin locus HS4 insulator element. Mol. Ther. 17 (2009) 667-674
45. Nielsen T., Jakobsson J., Rosenqvist N., and Lundberg C. Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants. BMC Biotechnol. 9 (2009) 13
46. West A.G., Gaszner M., and Felsenfeld G. Insulators: many functions, many mechanisms. Genes Dev. 16 (2002) 271-288
47. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
48. Bukovsky A.A., Song J.P., and Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73 (1999) 7087-7092
49. Chazal N., Singer G., Aiken C., Hammarskjold M.-L., and Rekosh D. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at Low pH no longer require Nef for optimal infectivity. J. Virol. 75 (2001) 4014-4018
50. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71 (1997) 5871-5877
51. Luo T., Douglas J.L., Livingston R.L., and Garcia J.V. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 241 (1998) 224-233
52. McClure M.O., Marsh M., and Weiss R.A. Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J. 7 (1988) 513-518
53. Akkina R.K., Walton R.M., Chen M.L., Li Q.X., Planelles V., and Chen I.S. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70 (1996) 2581-2585
54. Coil D.A., and Miller A.D. Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J. Virol. 78 (2004) 10920-10926
55. Carmo M., Dias J.D., Panet A., Coroadinha A.S., Carrondo M.J.T., Alves P.M., and Cruz P.E. Thermosensitivity of the reverse transcription process as an inactivation mechanism of lentiviral vectors. Hum. Gene Ther. 20 (2009) 1-9
56. DePolo N.J., Joyce J.D., Reed D., Philip P.L., Sheridan L., Townsend K., Sauter S.L., Jolly D.J., and Dubensky Jr. T.W. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. (2000) 218-222
57. Verhoeyen E., and Cosset F.-L. Surface-engineering of lentiviral vectors. J. Gene Med. 6 (2004) S83-S94
58. Cronin J., Zhang X.Y., and Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5 (2005) 387-398
59. Frecha C., Costa C., Negre D., Gauthier E., Russell S.J., Cosset F.-L., and Verhoeyen E. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112 (2008) 4843-4852
60. Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T., and Flake A.W. Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods 122 (2004) 131-139
61. Wong L.-F., Azzouz M., Walmsley L.E., Askham Z., Wilkes F.J., Mitrophanous K.A., Kingsman S.M., and Mazarakis N.D. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9 (2004) 101-111
62. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., and Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72 (1998) 9873-9880
63. Miyoshi H., Blomer U., Takahashi M., Gage F.H., and Verma I.M. Development of a self-inactivating lentivirus vector. J. Virol. 72 (1998) 8150-8157
64. Iwakuma T., Cui Y., and Chang L.J. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261 (1999) 120-132
65. Zufferey R., Donello J.E., Trono D., and Hope T.J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73 (1999) 2886-2892
66. Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., and Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101 (2000) 173-185
67. Zennou V., Serguera C., Sarkis C., Colin P., Perret E., Mallet J., and Charneau P. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat. Biotechnol. 19 (2001) 446-450
68. Sirven A., Pflumio F., Zennou V., Titeux M., Vainchenker W., Coulombel L., Dubart-Kupperschmitt A., and Charneau P. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96 (2000) 4103-4110
69. Follenzi A., Ailles L.E., Bakovic S., Geuna M., and Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25 (2000) 217-222
70. Croyle M.A., Callahan S.M., Auricchio A., Schumer G., Linse K.D., Wilson J.M., Brunner L.J., and Kobinger G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78 (2004) 912-921
71. Mühlebach M., Schmitt I., Steidl S., Stitz J., Schweizer M., Blankenstein T., Cichutek K., and Uckert W. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. J. Mol. Med. 81 (2003) 801-810
72. Carmo M., Alves A., Rodrigues A.F., Coroadinha A.S., Carrondo M.J.T., Alves P.M., and Cruz P.E. Stabilization of gammaretroviral and lentiviral vectors: from production to gene transfer. J. Gene Med. 11 (2009) 670-678
73. Carmo M., Panet A., Carrondo M.J.T., Alves P.M., and Cruz P.E. From retroviral vector production to gene transfer: spontaneous inactivation is caused by loss of reverse transcription capacity. J. Gene Med. 10 (2008) 383-391
74. Tonini T., Claudio P.P., Giordano A., and Romano G. Transient production of retroviral- and lentiviral-based vectors for the transduction of Mammalian cells. Methods Mol. Biol. 285 (2004) 141-148
75. Sastry L., Johnson T., Hobson M.J., Smucker B., and Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 9 (2002) 1155-1162
76. Eberle J., and Seibl R. A new method for measuring reverse transcriptase activity by ELISA. J. Virol. Methods 40 (1992) 347-356
77. Geraerts M., Willems S., Baekelandt V., Debyser Z., and Gijsbers R. Comparison of lentiviral vector titration methods. BMC Biotechnol. 6 (2006) 34
78. Ricks D.M., Kutner R., Zhang X.-Y., Welsh D.A., and Reiser J. Optimized lentiviral transduction of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 17 (2008) 441-450
79. Geraerts M., Michiels M., Baekelandt V., Debyser Z., and Gijsbers R. Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. 7 (2005) 1299-1310
80. Beyer W.R., Westphal M., Ostertag W., and von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprote: generation, concentration, and broad host range. J. Virol. 76 (2002) 1488-1495
81. Farson D., Witt R., McGuinness R., Dull T., Kelly M., Song J., Radeke R., Bukovsky A., Consiglio A., and Naldini L. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12 (2001) 981-997
82. Mitta B., Rimann M., and Fussenegger M. Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab. Eng. 7 (2005) 426-436
83. Chang L., Urlacher V., Iwakuma T., Cui Y., and Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6 (1999) 715-728
84. Böcker W., Rossmann O., Docheva D., Malterer G., Mutschler W., and Schieker M. Quantitative polymerase chain reaction as a reliable method to determine functional lentiviral titer after ex vivo gene transfer in human mesenchymal stem cells. J. Gene Med. 9 (2007) 585-595
85. Zhang B., Metharom P., Jullie H., Ellem K., Cleghorn G., West M., and Wei M. The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events. Genet. Vaccines Ther. 2 (2004) 6
86. Kutner R.H., Zhang X.-Y., and Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc. 4 (2009) 495-505
87. Wu Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology 1 (2004) 13
88. Nightingale S.J., Hollis R.P., Pepper K.A., Petersen D., Yu X.-J., Yang C., Bahner I., and Kohn D.B. Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 13 (2006) 1121-1132
89. Van Maele B., De Rijck J., De Clercq E., and Debyser Z. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J. Virol. 77 (2003) 4685-4694
90. Butler S.L., Hansen M.S.T., and Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7 (2001) 631-634
91. Le Doux J.M., Morgan J.R., Snow R.G., and Yarmush M.L. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J. Virol. 70 (1996) 6468-6473
92. C. Delenda, C. Gaillard, Real-time quantitative PCR for the design of lentiviral vector analytical assays, Gene Ther (2005) (12) S36-S50.
93. Kuate S., Wagner R., and Überla K. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene Med. 4 (2002) 347-355
94. Zhang X.-Y., La Russa V.F., and Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J. Virol. 78 (2004) 1219-1229
95. Nash K.L., and Lever A.M.L. Green fluorescent protein: green cells do not always indicate gene expression. Gene Ther. 11 (2004) 882-883
96. Nègre D., Mangeot P.E., Duisit G., Blanchard S., Vidalain P.O., Leissner P., Winter A.J., Rabourdin-Combe C., Mehtali M., Moullier P., Darlix J.L., and Cosset F.L. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 7 (2000) 1613-1623
97. Liu M.L., Winther B.L., and Kay M.A. Pseudotransduction of hepatocytes by using concentrated pseudotyped vesicular stomatitis virus G glycoprotein (VSV-G)-Moloney murine leukemia virus-derived retrovirus vectors: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J. Virol. 70 (1996) 2497-2502
98. Metharom P., Takyar S., Xia H.H., Ellem K.A.O., Macmillan J., Shepherd R.W., Wilcox G.E., and Wei M.Q. Novel bovine lentiviral vectors based on Jembrana disease virus. J. Gene Med. 2 (2000) 176-185
99. Klages N., Zufferey R., and Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2 (2000) 170-176
100. Derouazi M., Girard P., Van Tilborgh F., Iglesias K., Muller N., Bertschinger M., and Wurm F.M. Serum-free large-scale transient transfection of CHO cells. Biotechnol. Bioeng. 87 (2004) 537-545
101. Ansorge S., Lanthier S., Transfiguracion J., Durocher Y., Henry O., and Kamen A. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med. 11 (2009) 868-876
102. Pham P.L., Kamen A., and Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 34 (2006) 225-237
103. Baldi L., Muller N., Picasso S., Jacquet R., Girard P., Thanh H.P., Derow E., and Wurm F.M. Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol. Prog. 21 (2005) 148-153
104. Wurm F., and Bernard A. Large-scale transient expression in mammalian cells for recombinant protein production. Curr. Opin. Biotechnol. 10 (1999) 156-159
105. Durocher Y., Pham P.L., St-Laurent G., Jacob D., Cass B., Chahal P., Lau C.J., Nalbantoglu J., and Kamen A. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J. Virol. Methods 144 (2007) 32-40
106. Durocher Y., Perret S., and Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30 (2002) E9
107. Geisse S., and Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production. J. Struct. Funct. Genomics 6 (2005) 165-170
108. Park J.Y., Lim B.P., Lee K., Kim Y.G., and Jo E.C. Scalable production of adeno-associated virus type 2 vectors via suspension transfection. Biotechnol. Bioeng. 94 (2006) 416-430
109. Hildinger M., Baldi L., Stettler M., and Wurm F. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol. Lett. (2007)
110. Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods 33 (2004) 164-172
111. Pham P., Kamen A., and Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 34 (2006) 225-237
112. Godbey W.T., and Mikos A.G. Recent progress in gene delivery using non-viral transfer complexes. J. Control. Release 72 (2001) 115-125
113. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voigt K., and Kissel T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release 89 (2003) 113-125
114. Sun X., Goh P.E., Wong K.T., Mori T., and Yap M.G. Enhancement of transient gene expression by fed-batch culture of HEK 293 EBNA1 cells in suspension. Biotechnol. Lett. 28 (2006) 843
115. Toledo J.R., Prieto Y., Oramas N., and Sanchez O. Polyethylenimine-based transfection method as a simple and effective way to produce recombinant lentiviral vectors. Appl. Biochem. Biotechnol. 157 (2009) 538-544
116. Bartz S.R., Rogel M.E., and Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol 70 (1996) 2324-2331
117. Follenzi A., and Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346 (2002) 454-465
118. Reiser J., Harmison G., Kluepfel-Stahl S., Brady R.O., Karlsson S., and Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 15266-15271
119. Smith S.L., and Shioda T. Advantages of COS-1 monkey kidney epithelial cells as packaging host for small-volume production of high-quality recombinant lentiviruses. J. Virol. Methods 157 (2009) 47-54
120. Côté J., Garnier A., Massie B., and Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol. Bioeng. 59 (1998) 567-575
121. Garnier A., Cote J., Nadeau I., Kamen A., and Massie B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15 (1994) 145-155
122. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 7 (2000) 910-913
123. Kuroda H., Kutner R.H., Bazan N.G., and Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J. Virol. Methods 157 (2009) 113-121
124. Segura M.M., Garnier A., Durocher Y., Coelho H., and Kamen A. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng. 98 (2007) 789-799
125. Karolewski B.A., Watson D.J., Parente M.K., and Wolfe J.H. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene Ther. 14 (2003) 1287-1296
126. Coleman J.E., Huentelman M.J., Kasparov S., Metcalfe B.L., Paton J.F., Katovich M.J., Semple-Rowland S.L., and Raizada M.K. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol. Genomics 12 (2003) 221-228
127. G. Backliwal, M. Hildinger, V. Hasija, F.M. Wurm, High density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI, Biotechnology and Bioengineering 9999 (2007) n/a.
128. Tom R., Bisson L., and Durocher Y. Transient expression in HEK293-EBNA1 cells. In: Dyson M.R., and Durocher Y. (Eds). Methods Express: Expression Systems (2007), Scion Publishing Ltd., Bloxham, Oxfordshire, UK 203-223
129. Al Yacoub N., Romanowska M., Haritonova N., and Foerster J. Optimized production and concentration of lentiviral vectors containing large inserts. J. Gene Med. 9 (2007) 579-584
130. Miyazaki Y., Takamatsu T., Nosaka T., Fujita S., Martin T.E., and Hatanaka M. The cytotoxicity of human immunodeficiency virus type 1 Rev: implications for its interaction with the nucleolar protein B23. Exp. Cell Res. 219 (1995) 93-101
131. Kaplan A.H., and Swanstrom R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4528-4532
132. Sparacio S., Pfeiffer T., Schaal H., and Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther. 3 (2001) 602-612
133. Kafri T., van Praag H., Ouyang L., Gage F.H., and Verma I.M. A packaging cell line for lentivirus vectors. J. Virol. 73 (1999) 576-584
134. Broussau S., Jabbour N., Mullick A., Durocher Y., Tom R., Transfiguracion J., Gilbert R., and Massie B. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 16 (2008) 500-507
135. Cockrell A.S., Ma H., Fu K., McCown T.J., and Kafri T. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 14 (2006) 276-284
136. Xu K., Ma H., McCown T.J., Verma I.M., and Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3 (2001) 97-104
137. Seraphin K., Ralf W., and Klaus U. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene Med. 4 (2002) 347-355
138. Pacchia A.L., Adelson M.E., Kaul M., Ron Y., and Dougherty J.P. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282 (2001) 77-86
139. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem. 42 (1981) 65-82
140. Altenburg B.C., Via D.P., and Steiner S.H. Modification of the phenotype of murine sarcoma virus-transformed cells by sodium butyrate: effects on morphology and cytoskeletal elements. Exp. Cell Res. 102 (1976) 223-231
141. Gloger I., Arad G., and Panet A. Regulation of Moloney murine leukemia virus replication in chronically infected cells arrested at the G0/G1 phase. J. Virol. 54 (1985) 844-850
142. Gasmi M., Glynn J., Jin M.-J., Jolly D.J., Yee J.-K., and Chen S.-T. Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J. Virol. 73 (1999) 1828-1834
143. Jaalouk D., Crosato M., Brodt P., and Galipeau J. Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors. Virol. J. 3 (2006) 27
144. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene. Ther. 7 (2000) 910-913
145. Park F., Ohashi K., Chiu W., Naldini L., and Kay M.A. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat. Genet. 24 (2000) 49-52
146. Chazal N., and Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiol. Mol. Biol. Rev. 67 (2003) 226-237 table of contents
147. Ono A., and Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13925-13930
148. Popik W., Alce T.M., and Au W.-C. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J. Virol. 76 (2002) 4709-4722
149. Maziere J.C., Landureau J.C., Giral P., Auclair M., Fall L., Lachgar A., Achour A., and Zagury D. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed. Pharmacother. 48 (1994) 63-67
150. Holm K., Weclewicz K., Hewson R., and Suomalainen M. Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55gag associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J. Virol. 77 (2003) 4805-4817
151. Chen Y., Ott C.J., Townsend K., Subbaiah P., Aiyar A., and Miller W.M. Cholesterol supplementation during production increases the infectivity of retroviral and lentiviral vectors pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G). Biochem. Eng. J. 44 (2009) 199-207
152. Coroadinha A., Alves P., Santos S., Cruz P., Merten O.W., and Carrondo M. Retrovirus producer cell line metabolism: implications on viral productivity. Appl. Microbiol. Biotechnol. 72 (2006) 1125-1135
153. Merten O.W. State-of-the-art of the production of retroviral vectors. J. Gene Med. 6 (2004) S105-S124
154. Coroadinha A.S., Ribeiro J., Roldão A., Cruz P.E., Alves P.M., Merten O.W., and Carrondo M.J.T. Effect of medium sugar source on the production of retroviral vectors for gene therapy. Biotechnol. Bioeng. 94 (2006) 24-36
155. Coroadinha A.S., Silva A.C., Pires E., Coelho A., Alves P.M., and Carrondo M.J.T. Effect of osmotic pressure on the production of retroviral vectors: enhancement in vector stability. Biotechnol. Bioeng. 94 (2006) 322-329
156. Beer C., Meyer A., Muller K., and Wirth M. The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308 (2003) 137-146
157. Carmo M., Faria T.Q., Falk H., Coroadinha A.S., Teixeira M., Merten O.W., Geny-Fiamma C., Alves P.M., Danos O., Panet A., Carrondo M.J.T., and Cruz P.E. Relationship between retroviral vector membrane and vector stability. J. Gen. Virol. 87 (2006) 1349-1356
158. Kutner R., Puthli S., Marino M., and Reiser J. Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol. 9 (2009) 10
159. Cruz P.E., Almeida J.S., Murphy P.N., Moreira J.L., and Carrondo M.J.T. Modeling retrovirus production for gene therapy. 1. Determination of optimal bioreaction mode and harvest strategy. Biotechnol. Prog. 16 (2000) 213-221
160. Torashima T., Yamada N., Itoh M., Yamamoto A., and Hirai H. Exposure of lentiviral vectors to subneutral pH shifts the tropism from Purkinje cell to Bergmann glia. Eur. J. Neurosci. 24 (2006) 371-380
161. McTaggart S., and Al-Rubeai M. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. Biotechnol. Prog. 16 (2000) 859-865
162. Ghani K., Garnier A., Coelho H., Transfiguracion J., Trudel P., and Kamen A. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnol. Bioeng. 95 (2006) 653-660
163. Rodrigues T., Carrondo M.J.T., Alves P.M., and Cruz P.E. Purification of retroviral vectors for clinical application: biological implications and technological challenges. J. Biotechnol. 127 (2007) 520-541
164. Braas G., Searle P., Slater N., and Lyddiatt A. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 6 (1996) 211-228
165. Lyddiatt A., and O'Sullivan D.A. Biochemical recovery and purification of gene therapy vectors. Curr. Opin. Biotechnol. 9 (1998) 177-185
166. Yamada K., McCarty D.M., Madden V.J., and Walsh C.E. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 34 (2003) 1074-1078
167. Scherr M., Battmer K., Eder M., Schule S., Hohenberg H., Ganser A., Grez M., and Blomer U. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 9 (2002) 1708-1714
168. Marino M., Kutner R., Lajmi A., Nocumson S., and Reiser J. Development of scalable purification protocols for lentiviral vectors. Mol. Ther. 7 (2003) S178
169. Transfiguracion J., Jaalouk D.E., Ghani K., Galipeau J., and Kamen A. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 14 (2003) 1139-1153
170. Manilla P., Rebello T., Afable C., Lu X., Slepushkin V., Humeau L.M., Schonely K., Ni Y., Binder G.K., Levine B.L., Macgregor R.-R., June C.H., and Dropulic B. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 16 (2005) 17-25
171. Lusky M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum. Gene Ther. 16 (2005) 281-291
172. Thorne B.A., Takeya R.K., and Peluso R.W. Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene Ther. 20 (2009) 707-714
173. Mandel R.J., Burger C., and Snyder R.O. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp. Neurol. 209 (2008) 58-71
174. Evans J.T., and Garcia J.V. Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum. Gene Ther. 11 (2000) 2331-2339
175. Bukovsky A.A., Song J.-P., and Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73 (1999) 7087-7092
176. Ciuffi A., Mitchell R.S., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., and Bushman F.D. Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts. Mol. Ther. 13 (2006) 366-373
177. Mitchell R.S., Beitzel B.F., Schroder A.R.W., Shinn P., Chen H., Berry C.C., Ecker J.R., and Bushman F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) e234
178. Wang G.P., Levine B.L., Binder G.K., Berry C.C., Malani N., McGarrity G., Tebas P., June C.H., and Bushman F.D. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther. 17 (2009) 844-850
179. Montini E., Cesana D., Schmidt M., Sanvito F., Ponzoni M., Bartholomae C., Sergi L.S., Benedicenti F., Ambrosi A., Di Serio C., Doglioni C., von Kalle C., and Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24 (2006) 687-696
180. Rossi J.J. Dotting the I/'s and crossing the T/'s: integration analyses in transduced patient T cells. Mol. Ther. 17 (2009) 756-757
181. L. Sastry, K. Cornetta, Detection of Replication Competent Retrovirus and Lentivirus, Humana Press, 2008, pp. 243-263.
182. Kamen A., and Henry O. Development and optimization of an adenovirus production process. J. Gene Med. 6 (2004) S184-S192
183. Aucoin M.G., Perrier M., and Kamen A.A. Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol. Adv. 26 (2008) 73-88
184. Vaughan E.E., and Dean D.A. Intracellular trafficking of plasmids during transfection is mediated by microtubules. Mol. Ther. 13 (2006) 422-428
185. Elouahabi A., and Ruysschaert J.-M. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 11 (2005) 336-347
186. Collins L. Nonviral vectors. Methods Mol. Biol. 333 (2006) 201-226
187. Transfiguracion J., Bernier A., Arcand N., Chahal P., and Kamen A. Validation of a high-performance liquid chromatographic assay for the quantification of adenovirus type 5 particles. J. Chromatogr. B Biomed. Sci. Appl. 761 (2001) 187-194
188. Transfiguracion J., Bernier A., Voyer R., Coelho H., Coffey M., and Kamen A. Rapid and reliable quantification of reovirus type 3 by high performance liquid chromatography during manufacturing of Reolysin. J. Pharm. Biomed. Anal. 48 (2008) 598-605
189. Transfiguracion J., Coelho H., and Kamen A. High-performance liquid chromatographic total particles quantification of retroviral vectors pseudotyped with vesicular stomatitis virus-G glycoprotein. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 813 (2004) 167-173
190. Shen C.F., Meghrous J., and Kamen A. Quantitation of baculovirus particles by flow cytometry. J. Virol. Methods 105 (2002) 321-330
191. Wanisch K., and Yanez-Munoz R.J. Integration-deficient lentiviral vectors: a slow coming of age. Mol. Ther. (2009)